Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

McClellan Outlines Vision For Device User Fees, Third-Party Inspections

This article was originally published in The Gray Sheet

Executive Summary

Incoming FDA commissioner Mark McClellan, MD/PhD, is pledging to hold the agency to premarket review performance goals mandated under the "Medical Device User Fee and Modernization Act" if the bill becomes law

You may also be interested in...



FDA Tags Academic Researcher To Probe Advisory Panel Conflicts Of Interest

A joint conflict-of-interest study by FDA and the University of Maryland will survey attendees at the agency's April Circulatory System Devices Advisory Panel and National Mammography Quality Assurance Advisory Committee meetings, according to the project's primary investigator

FDA Tags Academic Researcher To Probe Advisory Panel Conflicts Of Interest

A joint conflict-of-interest study by FDA and the University of Maryland will survey attendees at the agency's April Circulatory System Devices Advisory Panel and National Mammography Quality Assurance Advisory Committee meetings, according to the project's primary investigator

Plano Contact Lens Warning Indicates Continued FDA Regulation As Devices

An FDA warning on the potential health risks of non-corrective (plano), decorative contact lenses signals that the products are unlikely to be regulated as cosmetics, as at least one manufacturer had hoped

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

MT017305

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel